We are focused on developing unique neurodegenerative
biomarkers and antibodies, applicable on
a broad range of platforms and useful
for accelerating clinical trials.
Koen Dewaele, CEO ADx NeuroSciences
ADx NeuroSciences ranks among the
top-3 companies worldwide in
neurodegenerative biomarker development.
Kevin Hrusovsky, CEO Quanterix, USA
We rely on the ADx-biomarkers for diagnosis
and identification of patients eligible for clinical trials.
They deliver robust and reliable results.
Early diagnosis is key to accelerate the search
for an effective therapy.
Prof. Dr. Sebastiaan Engelborghs,
neurologist at UAntwerp
ADx NeuroSciences is adding a lot of R&D expertise to
Euroimmun’s growing neurodegenerative biomarker portfolio.
Dr. Britta Brix
Head of department Neurodegenerative Diseases,
ADx NeuroSciences develops proprietary state-of-the-art biomarker-assays diagnosing a wide variety of neurodegenerative diseases and conditions. The ADx tests provide unique access to early detection of Alzheimer's disease, Parkinson's disease, and traumatic brain injury.
Both in vitro diagnostic companies as well as pharma companies benefit from the ADx technology. IVD companies utilize the ADx biomarkers and antibodies on various automated platforms and test kits. In search of novel therapies, pharmaceutical companies rely on the ADx assays and services to accelerate and improve the design of large clinical trials.
ADx was founded in 2011 by 4 pioneers in biomarker development and Alzheimer’s disease research. We combine more than 45 years of knowledge and experience and presents an impressive track record developing superior, highly performant and unique diagnostic biomarkers. The ADx markers allow accurate diagnosis even before symptoms appear, provide valuable patient information and bridge the gap between disease and novel treatments.